Endothelial regrowth after arterial injury: From vascular repair to therapeutics

Cardiovascular Research

Volumn 38, Issue 1, 1998, Pages 54-68

  Van Belle, Eric ^a   Bauters, Christophe ^a,c   Asahara, Takayaki ^b   Isner, Jeffrey M ^b  

^a UNIV LILLE   (France)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 1; PROTEOGLYCAN; VASCULOTROPIN;

ARTERY INJURY; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CARDIOVASCULAR RESPONSE; CELL DAMAGE; CELL GROWTH; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; MONOLAYER CULTURE; PRIORITY JOURNAL; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR SMOOTH MUSCLE; VASCULAR SURGERY;

ANIMALS; COMBINED MODALITY THERAPY; CORONARY DISEASE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; MYOCARDIAL REVASCULARIZATION;

EID: 0032051659     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(97)00326-X     Document Type: Review

References (184)

1. [1] Ueda M, Becker AE, Tsukada T, Numano F, Fujimoto T. Fibrocellular tissue response after percutaneous transluminal coronary angioplasty. An immunocytochemical analysis of the cellular composition. Circulation 1991;83:1327-1332.
2. [2] Gravanis MB, Roubin GS. Histopathologic phenomena at the site of percutaneous transluminal angioplasty: the problem of restenosis. Hum Pathol 1989;20:477-485.
3. [3] Austin GE, Norman NB, Hollman J, Tabei S, Phillips VF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-375.
4. [4] Schwartz RS, Holmes DR, Topol EJ. The restenosis paradigm revisited: an alternative proposal for cellular mechanisms. J Am Coll Cardiol 1992;20:1284-1293.
5. [5] McFadden EP, Bauters C, Lablanche JM, Quandalle P, Leroy F, Bertrand ME. Response of human coronary arteries to serotonin after injury by coronary angioplasty. Circulation 1993;88:2076-2085.
6. [6] Moncada S, Vane JR. Pharmacology and endogenous roles of prostanlandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1979;30:293-331.
7. [7] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-376.
8. [8] Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
9. [9] Ignarro LJ, Byrns RE, Wood KS. Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In: Vanhoutte PM, editor. Mechanisms of Vasodilatation. New York: Raven Press, 1988:427-435.
10. [10] Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
11. [11] Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthetize nitric oxide from L-arginine. Nature 1988;333:664-666.
12. [12] Schmidt HHW, Pollock JS, Nakane M, Gorsky LD, Föstermann U, Murad F. Purification of a soluble isoform of guanylyl cyclase-activating-factor synthase. Proc Natl Acad Sci USA 1991;88:365-369.
13. [13] Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-2012.
14. [14] Rubanyi GM, Vanhoutte PM. Nature of endothelium-derived relaxing factors: are there two relaxing mediators?. Cir Res 1987;61:1161-1167.
15. [15] Suzuki H, Chen G. Endothelium-derived hyperpolarizing factor (EDHF) an endogenous potassium-channel activator. TIPS, 1990:212-215.
16. [16] Hickey KA, Rubanyi GM, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248:C550-C556.
17. [17] Yanagisawa M, Kurthara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
18. [18] Levin ER. Endothelins. N Engl J Med 1995;333:356-363.
19. [19] Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
20. [20] Prins BA, Hu RM, Nazario B, et al. Prostaglandin E2 and prostacyclin inhibit the production and secretion of endothelin from cultured endothelial cells. J Biol Chem 1994;269:11938-11944.
21. [21] Caldwell PRB, Seegal BC, Hsu KC, Das M, Soffer RL. Angiotensin-converting enzyme: vascular endothelial localization. Science 1976;191:1050-1051.
22. [22] Kifor I, Dzau VJ. Endothelial renin-angiotensin pathway: evidence for intracellular synthesis and secretion of angiotensin. Circ Res 1987;60:422-428.
23. [23] Lilly LS, Pratt RE, Alexander RW, et al. Renin expression by vascular endothelial cells in culture. Circ Res 1985;57:312-318.
24. [24] Mohazzab KM, Kaminski PM, Wolin MS. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am J Physiol 1994;266:H2568-H2572.
25. [25] Gryglewski RJ, Palmer RMJ, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986;320:454-456.
26. [26] Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-H827.
27. [27] Mügge A, Elwell JH, Peterson TE, Harrison DG. Release of intact endothelium-dependent relaxing factor depends on endothelium superoxide dismutase activity. Am J Physiol 1991;260:C219-C225.
28. [28] Omar HA, Cherry PD, Mortelliti MP, Burke-Wolin T, Wolin MS. Inhibition of coronary artery superoxide dismutase attenuates endothelium-dependent and -independent nitrovasodilator relaxation. Circ Res 1991;69:601-608.
29. [29] Schwartz SM, Campbell CR, Campbell JH. Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-444.
30. [30] Di Corleto PE, Fox PL. Growth factor production by endothelial cells. In: Ryan U, editor. Endothelial cells. Boca Raton: CRC Press, 1988:51-61.
31. [31] Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expression by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1419-1424.
32. [32] Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 1991;68:450-456.
33. [33] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
34. [34] Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991;18:115-121.
35. [35] Fishman JA, Ryan GB, Karnovsky MJ. Endothelial regeneration in the rat carotid artery and the significance of endothelial denudation in the pathogenesis of myointimal thickening. Lab Invest 1975;32:339-351.
36. [36] Schwartz SM, Heimark RL, Majesky MW. Developmental mechanisms of underlying pathology of arteries. Physiol Rev 1990;70:1177-1209.
37. [37] Castellot JJ, Wright TC, Karnovsky MJ. Regulation of smooth muscle cell growth by heparin and heparan sulfates. Semin Thromb Hemost 1987;13:487-503.
38. [38] Scott-Burden T, Buhler FR. Regulation of smooth muscle proliferative phenotype by heparinoid-matrix interactions. Trends Pharmacol Sci 1988;9:94-98.
39. [39] Castellot JJ, Addonizio ML, Rosenberg RD, Karnovsky MJ. Cultured endothelial cells produce heparin-like inhibitor of smooth muscle cell growth. J Cell Biol 1981;90:372-379.
40. [40] Hoover R, Rosenburg R, Haering W, Karnovsky M. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vitro studies. Circ Res 1980;47:478-483.
41. [41] Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-626.
42. [42] Reilly CF, Kindy MS, Brown KE, Rosenberg RD, Sonenshein GE. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem 1989;264:6990-6995.
43. [43] Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured-rat carotid artery. Circ Res 1987;61:296-300.
44. [44] Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic-guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-1777.
45. [45] Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth muscle proliferation. Circulation 1993;87:V51-V55. (suppl. V).
46. [46] Guo J, Milhoan KA, Tuan RS, Lefer AM. Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury. Circ Res 1994;75:77-84.
47. [47] Hamon M, Vallet B, Bauters C, et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994;90:1357-1362.
48. [48] Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991;83:1057-1062.
49. [49] Wang B, Singer A, Tsao P, Drexler H, Kosek J, Cooke JP. Dietary arginine prevents atherosclerosis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol 1994;23:452-458.
50. [50] Ofosu FA, Modi GJ, Smith LM, Cerskus AL, Hirsh J, Blachjman MA. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways. Blood 1984;64:742-747.
51. [51] Stern D, Brett J, Harris K, Nawroth P. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol 1986;102:1971-1978.
52. [52] Loskutoff DJ, Edgington TS. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci USA 1977;74:3903-3907.
53. [53] Loskutoff DJ, Edgington TS. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 1981;256:4142-4145.
54. [54] Radomski WM, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;2:1057-1058.
55. [55] Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-646.
56. [56] Lam JYT, Chesebro JR, Steele PM, Dewarjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relations to a positive indium 111 labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986;8:1380-1386.
57. [57] Liu MW, Roubin GS, King SB III. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79:1374-1387.
58. [58] Thyberg J, Hedin U, Sjölund M. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 1990;10:966-990.
59. [59] Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-333.
60. [60] Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and in the hypercholesterolemic Yucatan micropig. Circulation 1994;89:2816-2821.
61. [61] Kakuta T, Currier JW, Haudenschild CC, Ryan TJ, Faxon DP. Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 1994;89:2809-2815.
62. [62] Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995;76:996-1002.
63. [63] Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty, A serial intravascular ultrasound study. Circulation 1996;94:35-43.
64. [64] Casscells W. Migration of smooth muscle and endothelial cells, Critical events in restenosis. Circulation 1992;86:723-729.
65. [65] Lindner V, Majack RA, Reidy M.A. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004-2008.
66. [66] Clowes AW, Collazzo RE, Karnovsky MJ. A morphologic and permeability study of luminal smooth muscle cells after arterial injury in the rat. Lab Invest 1978;39:141-150.
67. [67] Reidy MA, Clowes AW, Schwartz SM. Endothelial regeneration V. Inhibition of endothelial regrowth in arteries of rat and rabbit. Lab Invest 1983;49:569-575.
68. [68] Lindner V, Reidy MA, Fingerle J. Regrowth of arterial endothelium. Denudation with minimal trauma leads to complete endothelial cell regrowth. Lab Invest 1989;61:556-563.
69. [69] Weidinger FF, McLenachan JM, Cybulsky MI. Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery. Circulation 1990;81:1667-1679.
70. [70] Haudenschild CC, Schwartz SM. Endothelial regeneration II. Restitution of endothelial continuity. Lab Invest 1979;41:407-418.
71. [71] Stemerman MB, Spaet TH, Pitlick F, Cintron J, Lejnieks I, Tiell ML. The pattern of reendothelialization and intimal thickening. Am J Pathol 1977;87:125-142.
72. [72] Reidy MA, Standaert D, Schwartz SM. Inhibition of endothelial cell regrowth. Cessation of aortic endothelial cell replication after balloon catheter denudation. Arteriosclerosis 1982;2:216-220.
73. [73] Spagnoli LG, Pietra GG, Villaschi S, Johns LW. Morphometric analysis of gap junctions in regenerating arterial endothelium. Lab Invest 1982;46:139-148.
74. [74] Schweigerer L, Neufeld G, Friedman J. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987;325:257-259.
75. [75] Gospodarowicz D, Ferrara N, Haaparanta T, Neufeld G. Basic fibroblast growth factor: Expression in cultured bovine vascular smooth muscle cells. Eur J Cell Biol 1988;46:144-151.
76. [76] Hughes SE, Crossman D, Hall PA. Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res 1993;27:1214-1219.
77. [77] Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 1993;92:2408-2418.
78. [78] Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 1992;90:2044-2049.
79. [79] Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 1991;88:3739-3743.
80. [80] Lindner V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries, An en face study. Circ Res 1993;73:589-595.
81. [81] Vlodavsky I, Folkman J, Sullivan R, et al. Endothelial cell derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 1987;84:2292-2296.
82. [82] Lam MH, Bouchart M, Martel R, Fleser A, Leclerc G. Circulating serum levels of bFGF, VEGF, and TGF-b1 in patients undergoing PTCA. J Am Coll Cardiol 1996;27:363A. (Abstract).
83. [83] Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
84. [84] Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993;91:2235-2243.
85. [85] Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relationship between VEGF and NO in the regulation of endothelial integrity. Nature Med 1997;3:879-886.
86. [86] Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-112.
87. [87] Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci USA 1989;86:8421-8426.
88. [88] Berk BC, Taubman MB, Crajoe EJ, Fenton JW, Griendling KK. Thrombin signal transduction mechanisms in rat vascular smooth muscle cells. Calcium and protein kinase C-dependent and independent pathways. J Biol Chem 1990;265:17334-17340.
89. [89] Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 1991;84:432-435.
90. [90] Reidy MA. Endothelial regeneration VII. Interaction of smooth muscle cells with endothelial regrowth. Lab Invest 1988;59:36-43.
91. [91] Reidy MA, Schwartz SM. Endothelial regeneration III. Time course of intimal changes after small defined injury to rat aortic endothelium. Lab Invest 1981;44:301-308.
92. [92] Christensen BC, Chemnitz J, Tkocz I, Kim CM. Repair in arterial tissue. Endothelial regrowth, subendothelial tissue changes and permeability in the healing rabbit thoracic aorta. Acta Pathol Microbiol Scand 1979;87:265-273.
93. [93] Christensen S, Nielsen H. Permeability of arterial endothelium to plasma macromolecules. Atherosclerosis 1977;27:447-463.
94. [94] Walker LN, Ramsay MM, Bowyer DE. Endothelial healing following defined injury to rabbit aorta: depth of injury and mode of repair. Arteriosclerosis 1983;47:123-130.
95. [95] Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med 1994;330:1431-1438.
96. [96] Langille BL, O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986;231:405-407.
97. [97] Tronc F, Wassef M, Esposito B, Henrion D, Glagov S, Tedgui A. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996;16:1256-1262.
98. [98] Shimokawa H, Aarhus LL, Vanhoutte PM. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987;61:256-270.
99. [99] Shimokawa H, Flavahan NA, Vanhoutte PM. Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein. Circ Res 1989;65:740-753.
100. [100] Hamon M, Bauters C, McFadden EP, Escudero X, Lablanche JM, Bertrand ME. Hypersensitivity of human coronary segments to ergonovine 6 month after injury by coronary angioplasty: a quantitative angiographic study in consecutive patients undergoing single-vessel angioplasty. Eur Heart J 1996;17:890-895.
101. [101] Saroyan RM, Roberts MP, Light JT, et al. Differential recovery of prostacyclin and endothelium-derived relaxing factor after vascular injury. Am J Physiol 1992;262:H1449-H1457.
102. [102] Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22:S1-S14. (suppl. 4).
103. [103] Hughes SE, Hall PA. Overview of the fibroblast growth factor and receptor families: Complexity, functional diversity, and implications for future cardiovascular research. Cardiovasc Res 1993;27:1199-1203.
104. [104] Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci USA 1986;83:7297-7301.
105. [105] Burke PA, Lehmann-Bruinsma K, Powell JS. Vascular endothelial growth factor causes endothelial proliferation after vascular injury. Biochem Biophys Res Comm 1995;207:348-354.
106. [106] Takeshita S, Zheng LP, Brogi E, et al. Therapeutic angiogenesis: a single intra-arterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hindlimb model. J Clin Invest 1994;93:662-670.
107. [107] Bauters C, Asahara T, Takeshita S, et al. Physiologic assessment of angiogenesis induced by a single intra-arterial bolus of vascular endothelial growth factor in the rabbit ischemic hindlimb. Am J Physiol 1994;267:H1263-H1271.
108. [108] Unger EF, Banai S, Shou M, et al. Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. Am J Physiol 1994;266:H1588-H1595.
109. [109] Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-2189.
110. [110] Lazarous DF, Shou M, Scheinowitz M, et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996;94:1074-1082.
111. [111] Veomett G, Kuszynski C, Kazakoff P, Rizzino A. Cell density regulates the number of cell surface receptors for fibroblast growth factors. Biochem Biophys Res Comm 1989;159:694-700.
112. [112] Meurice T, Bauters C, Auffray JL, et al. Basic fibroblast growth factor restores endothelium-dependent responses after balloon injury of rabbit arteries. Circulation 1996;93:18-22.
113. [113] Bjornsson TD, Dryjski M, Tluczek J, et al. Acidic fibroblast growth factor promotes vascular repair. Proc Natl Acad Sci USA 1991;88:8651-8655.
114. [114] Meurice T, Bauters C, Vallet B, et al. Basic fibroblast growth factor restores endothelium-dependent responses of hypercholesterolemic rabbit thoracic aorta. Am J Physiol 1996;272:H613-H617.
115. [115] Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest 1987;79:170-174.
116. [116] Weidinger FF, McLenachan JM, Cybulsky MI, et al. Hypercholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery. Circulation 1991;84:755-767.
117. [117] Jayakody L, Senaratne M, Thomson A, Kappagoda T. Endothelium-dependent relaxation in experimental atherosclerosis in the rabbit. Circ Res 1987;60:251-264.
118. [118] Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990;67:1301-1308.
119. [119] Keaney JF, Xu A, Cunningham D, Jackson T, Frei B, Vita JA. Dietary probucol preserves endothelial function in cholesterol-fed rabbits by limiting vascular oxydative stress and superoxide generation. J Clin Invest 1995;95:2520-2529.
120. [120] Ohara Y, Peterson TE, Sayegh HS, Subramanian RR, Wilcox JN, Harrison DG. Dietary correction of hypercholesterolemia in the rabbit normalizes endothelial superoxide anion production. Circulation 1995;92:898-903.
121. [121] Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 1991;68:106-113.
122. [122] Winkles JA, Friesel R, Burgess WH, et al. Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial growth factor). Proc Natl Acad Sci USA 1987;84:7124-7128.
123. [123] Seetharam L, Gotoh N, Maru Y, Neufeld G, Yamaguchi S, Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995;10:135-147.
124. [124] Tuder RM, Flook BE, Voelkel NF. Increased gene expression of VEGF and the VEGF receptors KDR/Flk and Fit in lungs exposed to acute or to chronic hypoxia: Modulation of gene expression by nitric oxide. J Clin Invest 1995;95:1798-1807.
125. [125] Ferrara N. Vascular endothelial growth factor. Trends Cardiovasc Med 1993;3:244-250.
126. [126] Asahara T, Bauters C, Pastore C, et al. Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 1995;91:2793-2801.
127. [127] Concina P, Arnal JF, Barbacanne MA, Pieraggi MT, Fournial G, Bayard F. Effect of bFGF, VEGF and estradiol on endothelial proliferation and neointimal hyperplasia in balloon-injured rat carotid. Arch Mal Coeur 1997;90:546. (Abstract).
128. [128] Callow AD, Choi ET, Trachtenberg JD, et al. Vascular permeability factor accelerates endothelial regrowth following balloon angioplasty. Growth Factors 1994;10:223-228.
129. [129] Lindner V, Reidy MA. Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler Thromb Vasc Biol 1996;16:1399-1405.
130. [130] Asahara T, Chen D, Tsurumi Y, et al. Accelerated Restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 1996;94:3291-3302.
131. [131] Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent-placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
132. [132] Serruys PW, DeJaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty with coronary artery disease. N Engl J Med 1994;331:489-495.
133. [133] Hoffmann R, Mintz GS, Dusaillant GR, et al. Patterns and mechanisms of in-stent restenosis, A serial intravascular ultrasound study. Circulation 1996;94:1247-1254.
134. [134] Kearney MA, Pieczek A, Haley L, et al. Histopathology of stent restenosis in patients with peripheral artery disease. Circulation 1997;95:1998-2002.
135. [135] Popma JJ, Satler LF, Pichard AD, et al. Vascular complications after balloon and new device angioplasty. Circulation 1993;88:1569-1578.
136. [136] Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting: the multicenter registry of acute and elective Gianturco-Roubin stent placement. Circulation 1994;89:1126-1137.
137. [137] Nakamura S, Colombo A, Gaglione A, et al. Intracoronary ultrasound observations during stent implantation. Circulation 1994;89:2026-2034.
138. [138] Barragan P, Sainsous J, Silvestri M, et al. Ticlopidine and subcutaneous heparin as an alternative regimen following coronary stenting without coumadin. Cathet Cardiovasc Diag 1994;32:133-138.
139. [139] Van Belle E, McFadden EP, Lablanche J-M, Bauters C, Hamon M, Bertrand ME. Two-pronged antiplatelet therapy with aspirin and ticlopidin without systematic anticoagulation: an alternative therapeutic strategy after bailout stent implantation. Coronary Artery Dis 1995;6:341-345.
140. [140] Clowes AW. Improving the interface between biomaterials and the blood, The gene therapy approach. Circulation 1996;93:1319-1320.
141. [141] Palmaz JC, Windeler SA, Garcia F, Tio FO, Sibbitt RR, Reuter SR. Atherosclerotic rabbit aortas: expandable intraluminal grafting. Radiol 1986;160:723-726.
142. [142] Hehrlein C, Gollan C, Donges BS, et al. Low-dose radioactive endovascular stents prevent smooth muscle cell proliferation and neointimal hyperplasia in rabbits. Circulation 1995;92:1570-1575.
143. [143] Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation 1987;76:450-457.
144. [144] Hardhammar PA, van Beusekom HMM, Emmanuelsson HU, et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 1996;93:423-430.
145. [145] van Beusekom HMM, Van der Giessen WJ, van Suylen RJ, Bos E, Bosman FT, Serruys PW. Histology after stenting of human vein bypass grafts: observations from surgically excised grafts 3 to 320 days after stent implantation. J Am Coll Cardiol 1993;21:45-54.
146. [146] Anderson PG, Bajaj RK, Baxley WA, Roubin GS. Vascular pathology of balloon-expandable flexible coil stents in humans. J Am Coll Cardiol 1992;19:372-381.
147. [147] Van Belle E, Tio FO, Couffinhal T, Maillard L, Passeri J, Isner JM. Stent endothelialization: Time course, impact of catheter delivery, feasibility of recombinant protein administration, and response to cytokine expedition. Circulation 1997;94:438-448.
148. [148] Van Belle E, Tio FO, Chen D, Maillard L, Kearney M, Isner JM. Passivation of metallic stents following arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J Am Coll Cardiol 1997;29:1371-1379.
149. [149] Van Belle E, Maillard L, Tio FO, Isner JM. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem Biophys Res Comm 1997;235:311-316.
150. [150] Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. Circulation 1996;94:2909-2914.
151. [151] Van Belle E, Bauters C, Wernert N, et al. Angiotensin converting enzyme inhibition prevents proto-oncogene expression in the vascular wall after injury. J Hypertension 1995;13:105-112.
152. [152] Powell JS, Müller RKM, Kuhn H, Hefti F, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989;245:186-188.
153. [153] Farhy RD, Carretero OA, Ho KL, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 1993;72:1202-1210.
154. [154] Van Belle E, Vallet B, Auffray JL, et al. NO synthesis is involved in structural and functional effects of ACE inhibitors in injured arteries. Am J Physiol 1996;270:H298-H305.
155. [155] Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 1991;18:II37-II42. Suppl. II.
156. [156] Mancini J, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinalapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-265.
157. [157] Van Belle E, Meurice T, Fermin OT, et al. ACE inhibition accelerates endothelial regrowth in vivo: A possible explanation for the benefit observed with ACE inhibitors following balloon angioplasty. Biochem Biophys Res Comm 1997;231:577-581.
158. [158] Bell L, Madri JA. Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol 1990;137:7-12.
159. [159] Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995;95:651-657.
160. [160] Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
161. [161] Light JT, Bellan JA, Chen IL, et al. Angiopeptin enhances acetylcholine-induced relaxation and inhibits intimal hyperplasia after vascular injury. Am J Physiol 1993;265:H1265-H1274.
162. [162] Farhy RD, Ho KL, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Comm 1991;182:283-288.
163. [163] Levy H, Boas EP. Coronary artery disease in women. JAMA 1936;107:97-102.
164. [164] Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula A, Wing RR. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-646.
165. [165] Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-1075.
166. [166] Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerosis coronary arteries. Circulation 1990;81:1680-1687.
167. [167] Chen SJ, Li H, Durand J, Oparil S, Chen YF. Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. Circulation 1996;93:577-584.
168. [168] Venkov CD, Rankin B, Vaughan DE. Identification of authentic estrogen receptor expression in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996;94:727-733.
169. [169] Kim-Schulze S, McGowan KA, Hubchak SC, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996;94:1402-1407.
170. [170] Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995;91:755-763.
171. [171] Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation 1997;95:1505-1514.
172. [172] Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997;95:1768-1772.
173. [173] Rami J, Elhage R, Philippe M, et al. Effect of estradiol on the endothelium-dependent relaxation in rat aorta. Arch Mal Coeur 1997;90:546. (Abstract).
174. [174] Herring MB, Gardner A, Glover J. A single staged procedure for seeding vascular grafts with autogenous endothelium. Surgery 1978;84:498-504.
175. [175] Berinyi LK, Conte MS, Mulligan RC. Repopulation of injured arteries with genetically modified endothelial cells. J Vasc Surg 1992;15:932-934.
176. [176] Thompson MM, Budd JS, Eady SL, James RFL, Bell PRF. A method to transluminally seed angioplasty sites with endothelial cells. Eur J Vasc Surg 1993;7:113-121.
177. [177] Thompson MM, Budd JS, Eady SL. Platelet deposition after angioplasty is abolished by restoration of the endothelial cell monolayer. J Vasc Surg 1994;19:478-486.
178. [178] Conte MS, Birinyi LK, Miyata T, et al. Efficient repopulation of denuded rabbit arteries with autologous genetically modified endothelial cells. Circulation 1994;89:2161-2169.
179. [179] Conte MS, Choudhry RP, Shirakowa M, Fallon JT, Birinyi LK. Endothelial cell seeding fails to attenuate intimal thickening in balloon-injured rabbit arteries. J Vasc Surg 1995;21:413-421.
180. [180] Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964-967.
181. [181] Asahara T, Krasinski KL, Chen D, et al. Circulating endothelial progenitor cells in peripheral blood incorporate into re-endothelialization after vascular injury. Circulation 1997;96:I-725. (Abstract).
182. [182] Dichek DA, Neville RF, Zwiebel JA, Freeman SM, Leon MB, Anderson WF. Seeding of intravascular stents with genetically engineered endothelial cells. Circulation 1989;80:1347-1353.
183. [183] Flugelman MY, Virmani R, Leon MB, Bowman RL, Dichek DA. Genetically engineered endothelial cells remain adherent and viable after stent deployment and exposure to flow in vitro. Circ Res 1992;70:348-354.
184. [184] Dunn PF, Newman KD, Jones M, et al. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo. Circulation 1996;93:1439-1446.